Finally, a Chinese study (13) investigated rituximab with short-term glucocorticoids (35 participants, median age 51 years) versus rituximab alone (31 participants, median age 50 years) in patients with PLA2R antibody-positive MGN, with no specific trial registration provided. The gene discussed is PLA2R1; the disease is idiopathic membranous glomerulonephritis.